OBJECTIVE: The usefulness of repeated fine-needle cytology (FNC) in thyroid nodules with benign cytology remains unknown. We analyzed the relevance of repeated FNC to detect suspicious or malignant (S/M) cytologies and carcinomas. DESIGN: A retrospective study (1983-2004) was conducted in our endocrinology department. METHODS: We reviewed the reports of 895 adequate FNC performed in 298 patients (298 nodules) during a mean follow-up of 5 years. We compared the nodules with at least one suspicious or malignant FNC (S/M nodules) with nodules with repeatedly benign (RB) FNC (RB nodules). RESULTS: Among the nodules with initial benign cytology, we found 35 nodules with one or more later suspicious or malignant results. The interval between the first FNC and the first S/M FNC was 2.9 years. The probability for a nodule to have a repeated benign FNC decreases with time and with the number of FNC. We did not find any clinical or ultrasonographic characteristics related to an S/M cytology. Seven cancers were detected by the second or the third FNC with S/M results. The proportion of cancers among S/M nodules was similar when S/M cytology appears during the first, the second, or the third FNC. CONCLUSIONS: We suggest to repeat FNC up to three adequate samples in the follow-up of thyroid nodules so as not to miss the presence of malignant neoplasm.
OBJECTIVE: The usefulness of repeated fine-needle cytology (FNC) in thyroid nodules with benign cytology remains unknown. We analyzed the relevance of repeated FNC to detect suspicious or malignant (S/M) cytologies and carcinomas. DESIGN: A retrospective study (1983-2004) was conducted in our endocrinology department. METHODS: We reviewed the reports of 895 adequate FNC performed in 298 patients (298 nodules) during a mean follow-up of 5 years. We compared the nodules with at least one suspicious or malignant FNC (S/M nodules) with nodules with repeatedly benign (RB) FNC (RB nodules). RESULTS: Among the nodules with initial benign cytology, we found 35 nodules with one or more later suspicious or malignant results. The interval between the first FNC and the first S/M FNC was 2.9 years. The probability for a nodule to have a repeated benign FNC decreases with time and with the number of FNC. We did not find any clinical or ultrasonographic characteristics related to an S/M cytology. Seven cancers were detected by the second or the third FNC with S/M results. The proportion of cancers among S/M nodules was similar when S/M cytology appears during the first, the second, or the third FNC. CONCLUSIONS: We suggest to repeat FNC up to three adequate samples in the follow-up of thyroid nodules so as not to miss the presence of malignant neoplasm.
Authors: Frederico F R Maia; Patrícia S Matos; Elizabeth J Pavin; José Vassallo; Denise E Zantut-Wittmann Journal: Endocrine Date: 2011-04-16 Impact factor: 3.633
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Christine E Cherella; Henry A Feldman; Monica Hollowell; Danielle M Richman; Edmund S Cibas; Jessica R Smith; Trevor E Angell; Zhihong Wang; Erik K Alexander; Ari J Wassner Journal: J Clin Endocrinol Metab Date: 2018-09-01 Impact factor: 5.958
Authors: Nigel Glynn; Mark J Hannon; Sarah Lewis; Patrick Hillery; Mohammed Al-Mousa; Arnold D K Hill; Frank Keeling; Martina Morrin; Christopher J Thompson; Diarmuid Smith; Derval Royston; Mary Leader; Amar Agha Journal: BMC Endocr Disord Date: 2016-08-02 Impact factor: 2.763
Authors: Marco Medici; Xiaoyun Liu; Norra Kwong; Trevor E Angell; Ellen Marqusee; Matthew I Kim; Erik K Alexander Journal: BMC Med Date: 2016-01-27 Impact factor: 8.775